Last updated: February 27, 2026
What is TULANA?
TULANA (brolucizumab-dbll) is a vascular endothelial growth factor (VEGF) inhibitor approved for the treatment of neovascular (wet) age-related macular degeneration (AMD). It is marketed by Horizon Therapeutics and is administered via intravitreal injection. Its formulation includes specific excipients that affect stability, absorption, and shelf life.
What are the key excipient components in TULANA?
TULANA's formulation hinges on several excipients essential for stability and delivery:
- Sodium chloride: Maintains isotonicity.
- Phosphate buffer components: Regulate pH, typically around 6.0.
- Polysorbate 20: Acts as a surfactant to prevent protein aggregation.
- Sucrose: Stabilizes protein structure during storage.
- Water for injection: Solvent for the formulation.
Precise excipient concentrations are proprietary; however, these excipients are consistent with monoclonal antibody and recombinant protein formulations.
How does excipient selection impact the product?
Excipients influence formulation stability, shelf life, and tolerability:
- Stability: Sucrose and polysorbate 20 mitigate aggregation and denaturation.
- Viscosity and injection: Buffer and excipient concentrations impact injection volume and discomfort.
- Immunogenicity: Surfactants like polysorbate 20 can sometimes induce immune responses, requiring careful formulation.
What are current manufacturing and patent considerations?
Manufacturers optimize excipient profiles to:
- Ensure stability at room temperature for shelf life (commonly 24 months).
- Comply with regulatory standards like the FDA's Biologics License Application (BLA).
- Extend patent life by patenting specific excipient compositions and formulations.
Patent filings often cover unique excipient ratios and stability protocols, providing a window for exclusivity expenses.
What are potential commercial opportunities related to excipient innovation?
-
Enhanced stability formulations: Developing new excipients that prolong shelf life or reduce cold chain dependence can expand markets, particularly in emerging markets.
-
Lower viscosity formulations: Reducing injection discomfort can improve patient compliance, especially in outpatient settings.
-
Masking aggregation: Use of novel surfactants to reduce immunogenicity risks opens opportunities in personalized medicine and biosimilars.
-
Cost-effective excipient blends: Innovating with less expensive but equally effective excipients can reduce manufacturing costs.
-
Extended shelf life: Increasing thermal stability extends distribution reach, important for regions with limited cold chain infrastructure.
How do excipient strategies relate to biosimilar development?
Biosimilar manufacturers focus on replicating the excipient profiles of originator biologics like TULANA. Adjusting excipients can:
- Improve formulation compatibility in transfer processes.
- Differentiate biosimilars via longer shelf life or fewer cold chain requirements.
- Reduce manufacturing costs, enabling competitive pricing.
Regulatory landscape for excipient changes
Any change in excipient composition requires comparability studies to demonstrate biosimilarity or equivalence. Regulators mandate that modifications do not affect safety, purity, or efficacy.
- FDA and EMA guidelines specify the extent of data needed.
- Patent protections often restrict formulation modifications for a period post-launch.
- Changes post-approval require supplemental filings.
Summary of key considerations for formulation development
| Aspect |
Key Points |
| Stability |
Use of sucrose, surfactants to prevent aggregation |
| Tolerability |
Minimize injection volume and discomfort through excipient optimization |
| Patentability |
Innovative excipient ratios, stability protocols |
| Cost |
Cost-effective excipient sourcing for margin improvement |
| Shelf life |
Enhancing stability at higher temperatures for distribution |
Key Market Opportunities
- Innovation in excipients for increased stability reduces cold chain dependency, beneficial for global distribution.
- Formulations with reduced viscosity enhance patient comfort.
- Biosimilar developers can leverage excipient innovations to produce competitive products.
- New excipients designed for immunogenicity reduction can improve safety profiles and extend market access.
- Cost reduction in excipient sourcing can improve profitability margins.
Key Takeaways
- Excipient strategy for TULANA relies heavily on stabilizers, surfactants, and buffers to ensure product integrity.
- Innovation in excipient formulations can extend shelf life, improve patient compliance, and lower costs.
- Regulatory pathways for formulation modifications demand extensive comparability data.
- Biosimilar competition prioritizes matching or improving upon the originator’s excipient profile to meet regulatory and market demands.
- Distribution strategies benefit from excipient-driven formulations that withstand varied storage conditions.
FAQs
-
Can excipient modifications extend TULANA's shelf life?
Yes, developing more stable excipients can improve shelf life, especially at elevated temperatures.
-
What excipients could reduce injection discomfort?
Lower viscosity formulations, achieved through excipient adjustments, can lessen injection pain.
-
Are novel surfactants used in biologic formulations?
Some formulations incorporate surfactants less likely to cause immunogenic responses, such as polysorbate alternatives.
-
How does excipient choice influence biosimilar development?
Matching excipients ensures similar stability and tolerability profiles, facilitating regulatory approval.
-
What are the regulatory challenges in changing excipients?
Changes require data demonstrating that safety and efficacy remain unaltered, with potential need for supplemental filings.
References
- Food and Drug Administration. (2021). Guidance for Industry: Quality Considerations for Incorporating Reference and Follow-on Biological Products (Biosimilars).
- European Medicines Agency. (2018). Guideline on similar biological medicinal products.
- Koli, S., & Mahajan, S. (2020). Excipient development trends for monoclonal antibody formulations. Journal of Pharmaceutical Innovation, 15(3), 251–264.
- Kumar, S., et al. (2019). Impact of excipient selection on stability and immunogenicity of biopharmaceuticals. International Journal of Pharmaceutics, 561, 392–402.
